Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?

UBS likes Teva Pharmaceuticals among other generic drug companies, but should you?

Jul 24, 2014 at 8:54AM

UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals (NYSE:TEVA), a company that UBS believes will benefit from continued patent expirations , and generic drug introductions in the coming years. Hence, it's a long-term catalyst that UBS foresees, but in looking at Teva's competitors Actavis plc (NYSE:AGN) and Mylan Inc (NASDAQ:MYL), is it really the best opportunity of the bunch?

Underperformance equals value?
Teva, Actavis, and Mylan are all generic drug manufacturers, with Actavis and Mylan's stock easily outperforming Teva during the last five years.

ACT Chart

ACT data by YCharts

The generic drug market as a whole has benefited greatly from an era known as the patent cliff, a period between 2011 and 2016 where more than $130 billion of brand drug sales lose patent protection.

While many of the biggest drugs have already lost patent protection, other blockbusters such as Nexium, Celebrex, Cymbalta, Abilify, and Crestor are still on tap to lose protection. Hence, UBS must think that Teva's underperformance equals value now.

Why has Teva underperformed its peers?
In looking at Teva, Actavis, and Mylan from a fundamental perspective, the reasons for the former's underperformance couldn't be clearer. For one, the company's 8% annualized revenue growth rate over the last three years lags its peers; Actavis has grown at a 34.5% rate over the last three years.

While much of this growth comes from acquisitions, Actavis has also hit the jackpot with high profile generic drug launches, including Suboxone, Lamictal, Nuvigil, Onglyza, and Lidoderm in the last year.

For Mylan, its 8.2% growth rate over the last three years is marginally better than Teva, but the stock's near 20% gains this year can be traced to catalysts including its victory in gaining rights to the 50mg generic version for the blockbuster Celebrex later this year.  Also, Mylan got a big win at the expense of Teva.

Specifically, Teva is not just a generic drug manufacturer, but also sells brand products like the blockbuster multiple sclerosis drug Copaxone. In 2013, Copaxone generated $3.2 billion in the U.S. alone with growth of 11% year-over-year . In other words, this one drug accounts for more than 15% of total sales.

Teva is in the process of losing patent protection on Copaxone, but has been fighting relentlessly to protect some pieces of the blockbuster's revenue. Already, back in May Teva lost a court case to delay the generic form of Copaxone,  which means that Mylan will gain rights to sell a 20mg dosage of the drug. Now, the company's only hope lies in switching patients to a longer lasting 40mg dose, but the problem is that generic forms will still be cheaper, even with the dosing advantage.

As a result, Teva will lose at least a portion of its Copaxone revenue immediately, and a probably more. No doubt in part due to gains at Teva's expense,  Mylan's revenue growth is expected to accelerate in 2014 to 12.7% while analysts expect Teva's revenue to be flat in 2014 and down slightly in 2015.

Is Teva that cheap?
In retrospect, while Mylan and Actavis benefit from the patent cliff, Teva is about to feel the pinch of losing significant annual revenue from one single drug. Therefore, its generic business may create growth, but the losses from Copaxone will essentially make those generic gains fundamentally irrelevant, putting Teva in a multi-year slump of flat growth.

With that said, why would UBS call it the main beneficiary of the patent cliff, and not Mylan or Actavis? From a fundamental growth outlook, it significantly lags its peers into the next couple years, which is when the period will end. Therefore, UBS's call has to be valuation-related, right?


Forward P/E Ratio







As you can see, Teva does trade at a cheaper multiple than either Mylan or Actavis, but the real question is whether that discount is enough to justify its lack of growth. Essentially, you can pay 11.3 times forward earnings for a company that will have no growth over the next two years (per analyst estimates), or 13 times next year's earnings for a company that'll grow revenue 45% and 23%, respectively, in the same period in Actavis .

Foolish Thoughts
With all things considered, UBS might have got this one wrong, discounting the fact that Copaxone's lost patent means Teva will struggle even with the tailwind of the patent cliff over the next two years. Meanwhile, Mylan and Actavis both look cheap, and while the former has had some nice generic wins in recent months, Actavis' growth is unprecedented. As a result, at just 13 times next year's earnings, Actavis looks to be the best-in-class stock, one that still has a lot to gain.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Brian Nichols owns shares of ACTAVIS. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information